The presented mechanism of enhancement of the WT1TCR signaling by NFAT-regulated CAR can be modified to target different WT1-positive tumors, such as ovarian and lung carcinoma, by using inducible CAR specific to surface antigens such as mesothelin, Her2, or folate receptor alpha. The gene discussed is ERBB2; the disease is lung carcinoma.